Department of Medical Oncology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, China (mainland).
Department of Medical Oncology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China (mainland).
Med Sci Monit. 2019 Jul 29;25:5630-5639. doi: 10.12659/MSM.917968.
BACKGROUND The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is a prognostic factor in patients who have some types of malignant tumors. The aim of this study was to investigate the prognostic significance of the HALP score in patients with small cell lung cancer (SCLC) before first-line treatment with etoposide. MATERIAL AND METHODS A retrospective study included 178 patients with SCLC who received first-line chemotherapy with etoposide between September 2015 and May 2019. The baseline clinical characteristics and blood parameters were recorded. Univariate and multivariate analysis and Kaplan-Meier plots were used to identify the factors associated with progression-free survival (PFS). RESULTS The optimal cut-off values of the HALP score was determined by X-tile software to be 25.8. Univariate and multivariate analysis showed that in 178 patients, the HALP score, body mass index (BMI), and serum albumin levels had no prognostic significance. In the patient age group <65 years, a BMI ≥24 kg/m² was an independent prognostic factor (HR, 1.943; 95% CI, 1.251-3.018) (P=0.003). In the patient age group ≥65 years, a HALP score >25.8 was an independent positive prognostic factor for outcome following first-line treatment with etoposide (HR, 0.483; 95% CI, 0.270-0.865) (P=0.014). CONCLUSIONS In patients <65 years with SCLC who underwent first-line treatment with etoposide, a BMI ≥24 kg/m² an independent prognostic factor, and in patients ≥65 years, a HALP score >25.8 was an independent predictor of improved outcome, associated with increased PFS.
血红蛋白、白蛋白、淋巴细胞和血小板（HALP）评分是某些类型恶性肿瘤患者的预后因素。本研究旨在探讨一线依托泊苷治疗前小细胞肺癌（SCLC）患者 HALP 评分的预后意义。
本回顾性研究纳入了 178 例接受一线依托泊苷化疗的 SCLC 患者，入组时间为 2015 年 9 月至 2019 年 5 月。记录了患者的基线临床特征和血液参数。采用单因素和多因素分析及 Kaplan-Meier 图来确定与无进展生存期（PFS）相关的因素。
X-tile 软件确定 HALP 评分的最佳截断值为 25.8。单因素和多因素分析显示，在 178 例患者中，HALP 评分、体质量指数（BMI）和血清白蛋白水平与预后均无相关性。在年龄<65 岁的患者亚组中，BMI≥24kg/m²是独立的预后因素（HR，1.943；95%CI，1.251-3.018）（P=0.003）。在年龄≥65 岁的患者亚组中，一线依托泊苷治疗后 HALP 评分>25.8 是独立的阳性预后因素（HR，0.483；95%CI，0.270-0.865）（P=0.014）。
对于接受一线依托泊苷治疗的年龄<65 岁的 SCLC 患者，BMI≥24kg/m²是独立的预后因素，而对于年龄≥65 岁的患者，HALP 评分>25.8 是预后改善的独立预测因素，与 PFS 延长相关。
